

Product datasheet for **KN217312LP**

VEGFA Human Gene Knockout Kit (CRISPR)

Product data:

Product Type:	Knockout Kits (CRISPR)
Format:	2 gRNA vectors, 1 Luciferase-Puro donor, 1 scramble control
Donor DNA:	Luciferase-Puro
Symbol:	VEGFA
Locus ID:	7422
Components:	KN217312G1 , VEGFA gRNA vector 1 in pCas-Guide CRISPR vector (GE100002) KN217312G2 , VEGFA gRNA vector 2 in pCas-Guide CRISPR vector (GE100002) KN217312LPD , donor DNA containing left and right homologous arms and Luciferase-Puro functional cassette. GE100003 , scramble sequence in pCas-Guide vector
Disclaimer:	These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.
RefSeq:	NM_001025366 , NM_001025367 , NM_001025368 , NM_001025369 , NM_001025370 , NM_001033756 , NM_001171622 , NM_001171623 , NM_001171624 , NM_001171625 , NM_001171626 , NM_001171627 , NM_001171628 , NM_001171629 , NM_001171630 , NM_001204384 , NM_001204385 , NM_001287044 , NM_003376 , NM_001317010
UniProt ID:	P15692
Synonyms:	MVCD1; VEGF; VPF



[View online »](#)

Summary:

This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiotensin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020]

Product images:
